Literature DB >> 11408241

Macrolide-resistant Streptococcus pneumoniae in Canada during 1998-1999: prevalence of mef(A) and erm(B) and susceptibilities to ketolides.

D J Hoban1, A K Wierzbowski, K Nichol, G G Zhanel.   

Abstract

In this study (1998-1999), we collected 215 macrolide-resistant Streptococcus pneumoniae isolates from an ongoing Canadian Respiratory Organism Surveillance Study involving 23 centers representing all regions of Canada. The prevalence of erythromycin-resistant S. pneumoniae was 8% (215 of 2,688). Of the 215 isolates, 48.8% (105 of 215) were PCR positive for mef(A) and 46.5% (100 of 215) were PCR positive for erm(B). The ketolides telithromycin and ABT-773 demonstrated excellent activity against both mef(A) (MIC for 90% of strains [MIC(90)], 0.06 and 0.03 microg/ml, respectively) and erm(B) (MIC(90), 0.06 and 0.03 microg/ml, respectively) strains of S. pneumoniae.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11408241      PMCID: PMC90618          DOI: 10.1128/AAC.45.7.2147-2150.2001

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  24 in total

Review 1.  Introduction: the role of bacterial infection in chronic bronchitis.

Authors:  R Wilson; R Grossman
Journal:  Semin Respir Infect       Date:  2000-03

2.  In vitro development of resistance to telithromycin (HMR 3647), four macrolides, clindamycin, and pristinamycin in Streptococcus pneumoniae.

Authors:  T A Davies; B E Dewasse; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

3.  In vitro activity of ABT-773, a new ketolide, against recent clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis.

Authors:  A B Brueggemann; G V Doern; H K Huynh; E M Wingert; P R Rhomberg
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

4.  Antibiotic use in a Canadian Province, 1995-1998.

Authors:  A G Carrie; C J Metge; G G Zhanel
Journal:  Ann Pharmacother       Date:  2000-04       Impact factor: 3.154

5.  Antipneumococcal activity of ABT-773 compared to those of 10 other agents.

Authors:  T A Davies; L M Ednie; D M Hoellman; G A Pankuch; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2000-07       Impact factor: 5.191

6.  Characterization of a genetic element carrying the macrolide efflux gene mef(A) in Streptococcus pneumoniae.

Authors:  M Santagati; F Iannelli; M R Oggioni; S Stefani; G Pozzi
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

7.  Use of clindamycin disks To detect macrolide resistance mediated by ermB and mefE in Streptococcus pneumoniae isolates from adults and children.

Authors:  K Waites; C Johnson; B Gray; K Edwards; M Crain; W Benjamin
Journal:  J Clin Microbiol       Date:  2000-05       Impact factor: 5.948

Review 8.  Clinical significance of resistant organisms in otitis media.

Authors:  R Dagan
Journal:  Pediatr Infect Dis J       Date:  2000-04       Impact factor: 2.129

9.  Induction of ribosome methylation in MLS-resistant Streptococcus pneumoniae by macrolides and ketolides.

Authors:  P Zhong; Z Cao; R Hammond; Y Chen; J Beyer; V D Shortridge; L Y Phan; S Pratt; J Capobianco; K A Reich; R K Flamm; Y S Or; L Katz
Journal:  Microb Drug Resist       Date:  1999       Impact factor: 3.431

10.  Breakthrough pneumococcal bacteremia in patients being treated with azithromycin and clarithromycin.

Authors:  M A Kelley; D J Weber; P Gilligan; M S Cohen
Journal:  Clin Infect Dis       Date:  2000-10-13       Impact factor: 9.079

View more
  33 in total

1.  Phenotypes and genotypes of erythromycin-resistant pneumococci in Italy.

Authors:  Maria Pia Montanari; Marina Mingoia; Ileana Cochetti; Pietro Emanuele Varaldo
Journal:  J Clin Microbiol       Date:  2003-01       Impact factor: 5.948

2.  Efficacy of cethromycin, a new ketolide, against Streptococcus pneumoniae susceptible or resistant to erythromycin in a murine pneumonia model.

Authors:  E Azoulay-Dupuis; J Mohler; J P Bédos; C Barau; B Fantin
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

3.  Prevalence and molecular genetics of macrolide resistance among Streptococcus pneumoniae isolates collected in Finland in 2002.

Authors:  M Rantala; S Huikko; P Huovinen; J Jalava
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

Review 4.  Molecular detection of the macrolide efflux gene: to discriminate or not to discriminate between mef(A) and mef(E).

Authors:  Corné H W Klaassen; Johan W Mouton
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

5.  The macrolide resistance genes erm(B) and mef(E) are carried by Tn2010 in dual-gene Streptococcus pneumoniae isolates belonging to clonal complex CC271.

Authors:  Maria Del Grosso; John G E Northwood; David J Farrell; Annalisa Pantosti
Journal:  Antimicrob Agents Chemother       Date:  2007-08-20       Impact factor: 5.191

6.  Macrolide resistance in Streptococcus pneumoniae: Fallacy or fact?

Authors:  Jm Conly; Bl Johnston
Journal:  Can J Infect Dis       Date:  2002-01

7.  Bacteremic pneumococcal pneumonia associated with macrolide failure.

Authors:  J Dylewski; R Davidson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-01       Impact factor: 3.267

8.  Ketolide antimicrobial activity persists after disruption of interactions with domain II of 23S rRNA.

Authors:  Guy W Novotny; Lene Jakobsen; Niels M Andersen; Jacob Poehlsgaard; Stephen Douthwaite
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

Review 9.  Telithromycin.

Authors:  Keri Wellington; Stuart Noble
Journal:  Drugs       Date:  2004       Impact factor: 9.546

10.  Characterization and prevalence of MefA, MefE, and the associated msr(D) gene in Streptococcus pneumoniae clinical isolates.

Authors:  Melissa M Daly; Stella Doktor; Robert Flamm; Dee Shortridge
Journal:  J Clin Microbiol       Date:  2004-08       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.